Nymox to Report Results of New Phase 2 Study of NX-1207 for BPH

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Jan 16, 2008 - Nymox
Pharmaceutical Corporation (NASDAQ: NYMX) announced today that it
will be reporting results of a new Phase 2 clinical trial of
NX-1207 for benign prostatic hyperplasia (BPH). The Company expects
to complete statistical analysis within the next few weeks and will
be reporting the results once analysis is complete.

NX-1207 has shown positive results in 3 completed U.S. trials to
date. The Company's largest reported trial, a Phase 2 double-blind,
placebo controlled, randomized study, showed positive efficacy and
safety results for NX-1207 after 3 months in patients with BPH.
Overall, patients treated with NX-1207 showed after 3 months a mean
improvement of 9.35 points in AUA Symptom Score values, the
standard scale used to evaluate BPH drugs and treatments. This
improvement compares favorably to the 3.5 to 5 points reported in
published studies of currently approved drugs for BPH and reached
statistical significance (p=.017) when compared to placebo.
Subjects treated with NX-1207 also showed an overall significant
reduction in mean prostate volume. The results of the trial
demonstrated the excellent safety and side effect profile of
NX-1207. Subjects treated with NX-1207 had no serious side effects.
In particular, patients given NX-1207 had no (0%) significant
sexual side effects.

NX-1207 has also shown positive results in 5 follow-up studies
of available subjects from NX-1207 clinical trials. Patients have
shown durable benefits from NX-1207 treatment for up to 3 1/2 years
from the date of treatment. The results of a recently completed 2
year double blind follow-up study of subjects from the earlier
large Phase 2 trial showed that many patients required no further
treatment for 2 years after a single intraprostatic administration
of NX-1207 during an office visit. The latter results were
statistically significant (p less than .05) when compared to a
baseline matched group of placebo controls.

BPH afflicts approximately half of men over age 50 and close to
90% of men by age 80. The disorder causes difficulties with
urination associated with aging, such as urination at night, urge
to void frequently, hesitancy, weak stream, and other problems.

More information about Nymox is available at www.nymox.com,
email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements"
as defined in the United States Private Securities Litigation
Reform Act of 1995 that involve a number of risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and the actual results and future events could
differ materially from management's current expectations. The
conduct of clinical trials and the development of drug products
involve substantial risks and uncertainties and actual results may
differ materially from expectations. Promising early results do not
ensure that later stage or larger scale clinical trials will be
successful or will proceed as expected. Such factors are detailed
from time to time in Nymox's filings with the United States
Securities and Exchange Commission and other regulatory
authorities.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.